AusCann reports medicinal cannabis dog trial results promising

A Tasmanian-linked company has reported promising results from a US trial of a cannabis-based pain relief product for dogs.

Perth-based AusCann Group Holdings Limited - which sources cannabis resin from Tasmanian Alkaloids - said its CannPal Animal Therapeutics acquisition was shifting from pilot scale production to a commercial manufacturing partner to manufacture ingredients for developing animal health products using its MicroMAX technology.

"The veterinary pain and inflammation market is worth over $US1 billion globally and there is a need for viable treatment alternatives for dogs, particularly the elderly and compromised dogs where current treatments for pain and inflammation may be undesirable due to their potential negative side effect profiles or lack of effect," AusCann said.

MicroMAX involves encapsulating microscopic droplets of oil in special food.

AusCann said veterinary and owner scoring results from the US study supported the use of the CPAT-01 product for pain, lameness and better quality of life for client-owned dogs diagnosed with osteoarthritis.

"The positive indicators of CPAT-01 improving pain, inflammation and mood based on clinical and biochemical results give the company confidence moving forward with the development program for CPAT-01," AusCann said.

Forty-six dogs completed treatment during the trial, with their lameness assessed by vets and physical examinations at zero, 28 and 56 days.

IN OTHER NEWS:

AusCann said all the dogs treated with CPAT-01 showed significant improvement.

The dogs which had placebo treatments had worse mobility after 56 days.

The company said the study results would help inform the design of its development program.

AusCann had re-started working towards a meeting with the US Food and Drug Administration and the Center for Veterinary Medicine.

That would allow AusCann to share data from the study and get guidance on its US development and regulatory plan.